⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
VSTM News
Verastem, Inc.
Verastem Oncology Announces Positive Updated Results from RAMP 205 Evaluating Avutometinib Plus Defactinib in Combination with Standard-of-Care Chemotherapy in First-Line Metastatic Pancreatic Cancer
businesswire.com
VSTM
Verastem Oncology Doses First Patient in TARGET-D 201 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Pancreatic Cancer
businesswire.com
VSTM
Verastem Oncology to Host Investor Conference Call and Report Updated Data and Progress Across VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor TARGET-D Clinical Program
businesswire.com
VSTM
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
businesswire.com
VSTM
Verastem Oncology to Present at Jefferies Healthcare Conference
businesswire.com
VSTM
Form 8-K
sec.gov
VSTM
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors
businesswire.com
VSTM
Vast Therapeutics Presents Late-Breaking Phase 1 Data for Inhaled Therapy ALX1 at ATS 2026
businesswire.com
VSTM
Verastem Oncology to Present at Upcoming Investor Conferences
businesswire.com
VSTM
On World Ovarian Cancer Day, LGSOC Resource Guide Launches to Support People Living with Low-Grade Serous Ovarian Cancer
businesswire.com
VSTM